Perioperative Durvalumab for Resectable NSCLC: Updated Outcomes for Japanese Patients in AEGEAN.
Japanese patients with early-stage lung cancer receiving durvalumab after surgery showed encouraging survival benefits in this exploratory subgroup analysis.
We report prespecified exploratory Japanese subgroup analyses of EFS, disease-free survival (DFS), and overall survival (OS) (interim analyses; data cut-off [DCO] May 10, 2024); pCR (final analysis; DCO November 10, 2022); and safety. Trial Registration: ClinicalTrials.Gov Identifier NCT03800134.
What the study was
- Study design
- Phase 3 randomized controlled trial (Japanese subgroup prespecified exploratory analysis)
- Population
- Treatment-naïve Japanese patients with resectable NSCLC (n=79)
- Sample size
- 79
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Cancer science
Why it surfaced
Phase III AEGEAN updated data showing perioperative durvalumab benefit confirmed in Japanese subgroup; design_quality 2 (RCT); NOVEL_TREATMENT for perioperative PD-L1 blockade in resectable NSCLC.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.